Compass Therapeutics, Inc. (CMPX) – What Are Brokerages Thinking About This Stock?

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have received an average recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, twelve have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $10.25.

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. Piper Sandler upped their price objective on Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Thursday, October 15th. Wedbush set a $4.00 target price on Compass Therapeutics in a research note on Wednesday, September 23rd. Finally, Lifesci Capital downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 22nd.

Compass Therapeutics Stock Down 2.4%

Compass Therapeutics stock opened at $0.77 on Thursday. The stock has a 50-day simple moving average of $1.43 and a 200 day simple moving average of $3.21. Compass Therapeutics has a 12-month low of $0.73 and a 12-month high of $6.88. The stock has a market capitalization of $138.22 million, a price-to-earnings ratio of -1.92 and a beta of 1.02.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, sell-side analysts anticipate that Compass Therapeutics will post -0.47 EPS for the current year.

Institutional Trading of Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Compass Therapeutics during the second quarter worth approximately $24,707,000. Palo Alto Investors LP acquired a new stake in Compass Therapeutics during the 2nd quarter worth $12,771,670. Seven Fleet Capital Management LP grew its holdings in Compass Therapeutics by 65.4% during the 1st quarter. Seven Fleet Capital Management LP now owns 940,538 shares of the company’s stock worth $4,975,000 after acquiring an additional 371,791 shares during the period. Bank of America Corp DE raised its position in shares of Compass Therapeutics by 224.9% during the 1st quarter. Bank of America Corp DE now owns 865,613 shares of the company’s stock valued at $4,579,000 after acquiring an additional 599,179 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd raised its position in shares of Compass Therapeutics by 79.3% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 828,879 shares of the company’s stock valued at $4,385,000 after acquiring an additional 366,713 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.